Platelet aggregation pathway proteins

Platelet aggregation pathway proteins represent a diverse group of molecular targets, including receptors, enzymes, and adhesion molecules, that orchestrate the activation and clumping of platelets. Key components of this pathway include the P2Y12 ADP receptor, Cyclooxygenase-1 (COX-1), the Glycoprotein IIb/IIIa complex, and Protease-activated receptors (PARs). These proteins are essential for physiological hemostasis, where they facilitate the formation of a platelet plug at sites of vascular injury; however, their dysregulation leads to pathological arterial thrombosis. This pathway is the primary focus of antiplatelet therapy, which is critical for the management and prevention of cardiovascular events such as myocardial infarction and ischemic stroke. Drugs like aspirin and clopidogrel target specific proteins within this cascade to reduce platelet reactivity and prevent thrombus formation. Despite their efficacy, the therapeutic modulation of these proteins carries a significant risk of bleeding complications, necessitating careful patient selection and monitoring. This entry is classified as incorrect because it refers to a broad biological pathway rather than a single, specific molecular target.

Other names

Platelet activation pathwayHemostatic pathway proteinsAntiplatelet targetsPlatelet aggregation cascade

Inhibition of platelet activation and aggregation through various mechanisms including irreversible inhibition of Cyclooxygenase-1 (COX-1), antagonism of the P2Y12 adenosine diphosphate (ADP) receptor, blockade of the Glycoprotein IIb/IIIa (integrin alpha-IIb/beta-3) receptor, and antagonism of Protease-activated receptor 1 (PAR-1).